Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2

被引：9

作者：

Jeselsohn, Rinath ^{[1
,2
,3
]}

Schiff, Rachel ^{[4
,5
]}

Grinshpun, Albert ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Breast Oncol Ctr, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA

[4] Baylor Coll Med, Dept Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Mol & Cellular Biol, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA

来源：

CANCER CELL | 2021年 / 39卷 / 10期

关键词：

D O I：

10.1016/j.ccell.2021.08.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overcoming resistance to CDK4/6 inhibitors is a major clinical challenge. In this issue of Cancer Cell, Freeman-Cook et al. study mechanisms of resistance to CDK4/6 inhibitors by employing a CRISPRa screen. They identify the cyclin E-CDK2 axis and Myc signaling as key pathways of resistance and develop PF-06873600, a selective CDK2/4/6 inhibitor.

引用

页码：1302 / 1305

页数：5

共 50 条

[41] Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma (vol 23, pg 83, 2019)
Shody, K. S.
Vlachostergios, P. J.
Abdel-Malek, R. R.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (07) : 645 - 645
[42] Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation
Berthet, Cyril
Klarmann, Kimberly D.
Hilton, Mary Beth
Suh, Hyung Chan
Keller, Jonathan R.
Kiyokawa, Hiroaki
Kaldis, Philipp
DEVELOPMENTAL CELL, 2006, 10 (05) : 563 - 573
[43] Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
Inga-Marie Schaefer
Matthew L. Hemming
Meijun Z. Lundberg
Matthew P. Serrata
Isabel Goldaracena
Ninning Liu
Peng Yin
Joao A. Paulo
Steven P. Gygi
Suzanne George
Jeffrey A. Morgan
Monica M. Bertagnolli
Ewa T. Sicinska
Chen Chu
Shanshan Zheng
Adrian Mariño-Enríquez
Jason L. Hornick
Chandrajit P. Raut
Wen-Bin Ou
George D. Demetri
Sinem K. Saka
Jonathan A. Fletcher
British Journal of Cancer, 2022, 127 : 2072 - 2085
[44] Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
Schaefer, Inga-Marie
Hemming, Matthew L.
Lundberg, Meijun Z.
Serrata, Matthew P.
Goldaracena, Isabel
Liu, Ninning
Yin, Peng
Paulo, Joao A.
Gygi, Steven P.
George, Suzanne
Morgan, Jeffrey A.
Bertagnolli, Monica M.
Sicinska, Ewa T.
Chu, Chen
Zheng, Shanshan
Marino-Enriquez, Adrian
Hornick, Jason L.
Raut, Chandrajit P.
Ou, Wen-Bin
Demetri, George D.
Saka, Sinem K.
Fletcher, Jonathan A.
BRITISH JOURNAL OF CANCER, 2022, 127 (11) : 2072 - 2085
[45] Cell cycle stop during neutrophil differentiation in vivo does not involve p21cip1 but is accompagnied by a simultaneous downregulation of CDK2, CDK4, and CDK6.
Klausen, P
Bjerregaard, MD
Borregaard, N
Cowland, JB
BLOOD, 2003, 102 (11) : 173B - 173B
[46] CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, Shom
DeCristo, Molly J.
McAllister, Sandra S.
Zhao, Jean J.
TRENDS IN CELL BIOLOGY, 2018, 28 (11) : 911 - 925
[47] CDK4/6 inhibition in cancer: the cell cycle splicing connection
Sheppard, Karen E.
AbuHammad, Shatha
MOLECULAR & CELLULAR ONCOLOGY, 2019, 6 (06)
[48] Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein
Ikuta, M
Kamata, K
Fukasawa, K
Honma, T
Machida, T
Hirai, H
Suzuki-Takahashi, I
Hayama, T
Nishimura, S
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27548 - 27554
[49] The role of targeting CDK4/6 in cancer immunotherapy
Mengyu Sun
Lin Dong
Yu Wang
Chao Liu
Jiang Du
Bo Wang
Bofan Xing
Xiaofeng Yao
Yu Ren
Xuan Zhou
Holistic Integrative Oncology, 3 (1):
[50] TARGETING CDK4 AND 6 IN THE CLASSICAL SUBTYPE OF GLIOBLASTOMA
Madani, Daniel
Nixdorf, Sheri
McDonald, Kerrie
NEURO-ONCOLOGY, 2014, 16

← 1 2 3 4 5 →